BCL2 and Miyoshi myopathy: An interesting combination under evaluation including daratumumab is that with venetoclax, a selective and potent oral BCL-2 inhibitor that induces apoptosis in MM cell lines and primary samples, particularly those with t(11;14), a cytogenetic abnormality documented in near 20% of MM patients.